• 新的Ineos牛津抗菌性抗菌研究所是在青霉素发育的出生地建立
  • 对现有抗生素的抗性可以说是世界上最大的医疗保健挑战,称为“沉默的大流行”
  • Ineos捐赠是英国最大的捐款之一,并创造了一个新的伙伴关系模式,以解决这一紧急的全球问题
  • 研究人员将寻求为动物和人类开发新的药物,以及促进我们拥有的抗生素的更负责任使用
  • 吉姆奥尼尔勋爵说,“这个新的研究所可能是全球AMR挑战需求的突破片刻”

A new state of the art institute for antimicrobial research is to open at Oxford University thanks to a £100 million donation from INEOS.

ineos., one of the world’s largest manufacturing companies, and the University of Oxford are launching a new world-leading institute to combat the growing global issue of antimicrobial resistance (AMR), which currently causes an estimated 1.5 million excess deaths each year- and could cause over 10m deaths per year by 2050. Predicted to also create a global economic toll of $100 trillion by mid-century, it is arguably the greatest economic and healthcare challenge facing the world post-Covid.


It is bacterial resistance, caused by overuse and misuse of antibiotics, which arguably poses the broadest threat to global populations. The world is fast running out of effective antibiotics as bacteria evolve to develop resistance to our taken-for-granted treatments. Without urgent collaborative action to prevent common microbes becoming multi-drug resistant (commonly known as ‘superbugs’), we could return to a world where taken-for-granted treatments such as chemotherapy and hip replacements could become too risky, childbirth becomes extremely dangerous, and even a basic scratch could kill.

The rapid progression of antibacterial resistance is a natural process, exacerbated by significant overuse and misuse of antibiotics not only in human populations but especially in agriculture. Meanwhile, the field of new drug discovery has attracted insufficient scientific interest and funding in recent decades meaning no new antibiotics have been successfully developed since the 1980s.


延长ant的好处ibiotics the world has known since the 1940s requires both urgent new drug development, and better management of the existing drugs we have. It is natural that the microbes causing illness and infection gradually evolve to evade our treatments, but misuse of antibiotics - for instance overusing them and not finishing a full prescribed course - drastically accelerates this process.



Professor Louise Richardson, Vice Chancellor of the University of Oxford, said: “This is a wonderfully generous gift for which we are very grateful. It is another example of a powerful partnership between public and private institutions to address global problems. Oxford played a crucial role in the early development of antibiotics so it is only appropriate that we take the lead in developing a solution to antimicrobial resistance.”


Ineos Oxford Institute顾问的Surgeon David Sweetnam表示:“对抗生素的细菌性抗性的不断增长的威胁是我们时代最高的问题之一。所有现代手术和癌症治疗依赖于使用有效抗生素。失去这个珍贵的礼物将发出返回前抗生素时代。我们现在有一个非常狭窄的机会窗口,在这种情况下改变课程并防止不可易于的是不可避免的。

“If there is any positive lesson to be taken from the devastation of the Covid-19 pandemic, we’ve clearly seen that the only way out of such infectious disease crises is through brilliant scientific groundwork, laid well in advance. The vaccines which have been created in record time and which offer light at the end of the tunnel were developed using research conducted long before Covid-19 struck. It’s clear that we must be looking right now for new antibiotics with the same urgency as we have been for vaccines. The consequence of continued complacency doesn’t bear thinking about.”

Lord O’Neill of Gatley, the economist who led the Cameron government’s game-changing report on AMR in 2016, and co-authored the bookSuperbugs:对抗细菌的军备竞赛, said: “The combination of INEOS' success in the chemicals industry tied with the great minds of Oxford University and collaborating scientists is extremely promising. This new Institute, applying a model of reinvesting profit to drive further progress in the field, could be the breakthrough moment the global AMR challenge needs.”

The donation by INEOS is one of the largest ever given to a UK University, and builds on the company’s long commitment to philanthropy in the public health space. INEOS has already funded initiatives such as The Daily Mile, which aims to get the world’s children active every day, to tackle obesity and improve health and wellbeing.


Notes to editors:



Stephen Rouse, Head of University Communications: +44 (0)7753 688 232,

Chris McIntyre,战略通信经理:+44(0)1865 280 528,


Ursula Heath- Group Communications Manager
+44 (0)7979 507612

+44 (0) 20 7384 6980
+44 (0) 7931 377162

Emily Northcott (Media Zoo)
+44 (0) 20 7384 6980
+44(0)7876 033636

关于ineos. the world’s third largest chemical company. It has a turnover of $61bn and employs 26,000 people across 36 businesses, operating 194 sites in 29 countries throughout the world.

ineos.products make a significant contribution to saving life, improving health and enhancing standards of living for people around the world. Its businesses produce the raw materials that are essential in the manufacture of many goods: from paints to plastics, textiles to technology, medicines to mobile phones - chemicals manufactured by INEOS enhance almost every aspect of modern life. Its facilities provide the raw materials and products that meet society’s needs. Its scientific innovations are also helping in the move towards a lower carbon economy. And it is also playing a vital role in everything from reducing plastic waste to creating a more circular economy.

INEOS产品在医疗和制药领域发挥着至关重要的作用,提供超过300种产品,其中许多产品是欧盟/美国药典和美国FDA批准。ineos通过在英国,法国,德国和美国建造7个新的生产设施,直接回应Covid-19 Pandemice,通过世界卫生组织推荐的75%乙醇生产出手动消毒剂。在大流行高峰期间,每个设施每月供应100万瓶,可免费提供欧洲和美国欧洲和美国的前线医疗服务,并将尽快将瓶子送至公众。

INEOS目前可能是最着名的众所周知,目前在国际体育世界中的参与:它正在支持本AINALEIE和INEOS团队的目前的竞标将带回家36TH.Americas Cup, alongside backing The Grenadiers, Britain’s Tour de France winning cycle team, owns a 1/3rdstake in the Mercedes AMG Petronas F1 Team, and also owns football clubs OGC Nice and Lausanne Sport.

吉姆拉克利夫爵士(INEOS Founder and Chairman)

吉姆拉克利夫爵士was knighted in 2018 for services to business and investment. He is the founder and Chairman of INEOS. His company employs 26,000 people across 194 sites in 29 countries, and is among the 50 largest business in the world with sales of $61bn.

吉姆爵士为Ineos Oxford Institute提供了Ineos联合创始人Andy Currie和John Reece。The trio have funded several initiatives in public health to date, such as backing childrens’ running programmes GO Run for Fun and The Daily Mile, funding a new wing at the UK’s Defence and Military Rehabilitation Centre, funding a childrens’ A&E at Southampton General Hospital and donating critical supplies of INEOS hand sanitizer to the front lines of the Covid pandemic.

David Sweetnam (IOI Lead Advisor)

David Sweetnam来自一家外科医生,医生和护士,他在NHS作为一个骨科和创伤外科医生工作了超过30年。1998年被任命为伦敦主要教学医院之一的顾问,包括十年作为部门负责人,他作为武装部队的外科医生密切合作,以及纽曼基金会慈善董事长的审查员。

His experience as a surgeon has driven him to recognise the need for urgent action against AMR, not least because all modern surgery is premised on the use of effective antibiotics. His family history of surgical practice over three generations has given him a unique perspective regarding the alarming reduction in the effectiveness of antibiotics since the inception of The NHS in 1948. The menace of resistant infections from ‘superbugs’ increases year on year and will only get worse if left unchecked.

It was through his peripheral role as surgical advisor to the INEOS sports portfolio that he first shared his insights on the urgency of acting on the AMR ‘silent pandemic’ with the INEOS board, which has ultimately led to the founding of the INEOS Oxford Institute for Antimicrobial Research.


Oxford University has been placed number 1 in the Times Higher Education World University Rankings for the fifth year running, and at the heart of this success is our ground-breaking research and innovation. Oxford is world-famous for research excellence and home to some of the most talented people from across the globe. Our work helps the lives of millions, solving real-world problems through a huge network of partnerships and collaborations. The breadth and interdisciplinary nature of our research sparks imaginative and inventive insights and solutions.



Chris Schofield is Head of Organic Chemistry at the University of Oxford and a Fellow of the Royal Society. He is a professor of Organic Chemistry and a Fellow of Hertford College.

He has researched in antibiotic mode of action, biosynthesis and resistance since the start of his career in Oxford. His research group aims to contribute to a chemical understanding of biological systems, where possible of medicinal or agricultural importance. His group has pioneered work on metal-using enzymes that are involved in antibiotic biosynthesis and resistance as well as in human physiology, in the latter case including in the hypoxic response. His work has opened up new therapeutic possibilities for the treatment of bacterial infections and diseases including anaemia. His work is highly collaborative as demonstrated by his work with the Innovative Medicines Initiative to combat resistance to the penicillin family antibiotics (ENABLE project).

Professor Chris Schofield, Head of Organic Chemistry at Oxford, says:“IOI为我们提供了一个令人兴奋的机会,可以在一个研究所中链接词类合成化学和微生物学,其目的是在医学和农业中实现新的治疗方法。鉴于我们在抗生素发明中的历史记录记录,ineos捐赠意味着我们可以在英国这样做。“



Professor Walsh is also PI of DETER-XDR-CHINA, a study examining the spread and burden of AMR in public health sectors and hospitals in 30 provinces in China. He holds an honorary chair at the Chinese Agricultural University and was pivotal in the decision for the Chinese government to ban the use of colistin as a growth promoter on farms. He is also PI of CUT-SEC, a ‘one-health’ project in China and Thailand and has 12 active international projects, particularly in low-middle income countries.

Tim Walsh, Professor of Medical Microbiology at Oxford, says:"Just as the discovery of penicillin and subsequent antibiotics transformed modern medicine, the rapid and relentless growth of antimicrobial resistance poses one of the most serious threats to human life worldwide. Modern agriculture and healthcare both heavily reliant on antibiotics, which is why it is vital to address this issue as a humanitarian emergency and to bring together national and international expertise across scientific disciplines to develop new drugs and policies to tackle this global problem."